Prestige BioPharma Signs Contract for Contract Manufacturing of Benevira COVID-19 Vaccine in the US at BIO USA

[Asia Economy Reporter Lee Gwan-joo] Prestige BioPharma Group announced on the 20th that it has signed a contract for the contract manufacturing of COVID-19 vaccines with the U.S. company Benevira at the '2022 BIO International Convention (BIO USA)' held in San Diego, USA.

This contract is a comprehensive order covering from technology transfer and commercial-scale pilot production during the development stage to contract manufacturing of commercial batches after development completion. Prestige BioPharma and Prestige BioLogics will each be responsible for contract management and vaccine production. The specific contract amount was kept confidential due to business confidentiality.

The vaccine being developed by Benevira is undergoing multinational review with the goal of market release next year. According to the preclinical results of the COVID-19 prevention and treatment agent (β521) recently announced by Benevira, the preventive effect of β521 against the Delta and Omicron variants was found to be 99%.

Park So-yeon, CEO of Prestige BioPharma, said, “The vaccine business is a core business established as a triangular formation for group growth along with biosimilars and antibody new drugs. Recently, development and production efforts have continued in various areas such as endemic vaccines, HPV 9-valent vaccines, and influenza vaccines to realize actual sales,” adding, “In addition to securing an actual contract with Benevira at BIO USA, we are conducting detailed discussions with major potential clients, and we will make every effort to achieve additional contract orders.”

This content was produced with the assistance of AI translation services.